Akihiro Asai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Akihiro Asai has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
Alexander Miethke
Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
3 shared publicationsEriko Kishimoto
Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
3 shared publicationsKokoro Sakabe
Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
3 shared publicationsNita Sahani
Department of Anesthesiology and Critical Care, Shriners Hospital for Children, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
3 shared publications- Shingo Yasuhara
Department of Anesthesiology and Critical Care, Massachusetts General Hospital, Shriners Hospital for Children, and Harvard Medical School, Boston, MA, USA
3 shared publications Takanori Takebe
Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; College of Medicine, University of Cincinnati, Cincinnati, OH, USA; Institute of Research, Tokyo Medical and Dental University, Tokyo, Japan
3 shared publications
Latest Publications
- 5 September 2026
- Published by Elsevier in The Journal of Pediatrics
- Vol. 299
Hepatotoxicity in Adeno-Associated Virus Gene Therapy: Clinical Challenges and Strategic Solutions
- 5 September 2026
- Published by Elsevier in The Journal of Pediatrics
- Vol. 299
Hepatotoxicity in Adeno-Associated Virus Gene Therapy: Clinical Challenges and Strategic Solutions
- Open Access
- 2 October 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (7) , e70187
Pharmacokinetic Monitoring of JAK Inhibitor and Tacrolimus for Safe and Effective Management of Graft‐Versus‐Host Disease After Pediatric Liver Transplantation
Background and Aim: Though liver transplantation (LT) is effective for pediatric patients with end‐stage liver disease, it is associated with complications such as graft‐versus‐host disease (GVHD). In part due to its rarity and lack of standardized therapy, post‐LT GVHD is associated with a high mortality rate. While ruxolitinib (a JAK inhibitor) is approved for use in steroid‐refractory GVHD, its safety/efficacy post‐LT is undefined. Thus, this case study reports the use of ruxolitinib in a pediatric patient with post‐LT GVHD. Methods: A 5‐month‐old male underwent a deceased donor left lateral segment LT with an induction regimen of corticosteroid and tacrolimus. Four weeks post‐LT, the patient developed skin GVHD. Ruxolitinib was administered in combination with tacrolimus and posaconazole, both capable of drug–drug interactions with ruxolitinib via modulation of CYP3A4 activity. A pharmacokinetic (PK) study was conducted to evaluate the use of ruxolitinib to induce GVHD remission. Results: The ruxolitinib PK study revealed sufficient oral clearance and effective maximum serum concentration. Dosages of ruxolitinib, tacrolimus, and posaconazole were adjusted throughout the course of treatment based on GVHD severity (ruxolitinib) or their whole blood/plasma concentrations (tacrolimus and posaconazole). By 18 weeks after ruxolitinib initiation, skin GVHD lesions resolved and clinical remission was induced. The liver graft function was normal when assessed 40 months after the initial presentation of GVHD. Conclusions: This case illustrates the safe and effective PK ‐validated use of ruxolitinib with tacrolimus and posaconazole to successfully induce remission of post‐ LT GVHD in a pediatric patient.
- 2 October 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (7) , e70187
Open AccessPharmacokinetic Monitoring of JAK Inhibitor and Tacrolimus for Safe and Effective Management of Graft‐Versus‐Host Disease After Pediatric Liver Transplantation
Background and Aim: Though liver transplantation (LT) is effective for pediatric patients with end‐stage liver disease, it is associated with complications such as graft‐versus‐host disease (GVHD). In part due to its rarity and lack of standardized therapy, post‐LT GVHD is associated with a high mortality rate. While ruxolitinib (a JAK inhibitor) is approved for use in steroid‐refractory GVHD, its safety/efficacy post‐LT is undefined. Thus, this case study reports the use of ruxolitinib in a pediatric patient with post‐LT GVHD. Methods: A 5‐month‐old male underwent a deceased donor left lateral segment LT with an induction regimen of corticosteroid and tacrolimus. Four weeks post‐LT, the patient developed skin GVHD. Ruxolitinib was administered in combination with tacrolimus and posaconazole, both capable of drug–drug interactions with ruxolitinib via modulation of CYP3A4 activity. A pharmacokinetic (PK) study was conducted to evaluate the use of ruxolitinib to induce GVHD remission. Results: The ruxolitinib PK study revealed sufficient oral clearance and effective maximum serum concentration. Dosages of ruxolitinib, tacrolimus, and posaconazole were adjusted throughout the course of treatment based on GVHD severity (ruxolitinib) or their whole blood/plasma concentrations (tacrolimus and posaconazole). By 18 weeks after ruxolitinib initiation, skin GVHD lesions resolved and clinical remission was induced. The liver graft function was normal when assessed 40 months after the initial presentation of GVHD. Conclusions: This case illustrates the safe and effective PK ‐validated use of ruxolitinib with tacrolimus and posaconazole to successfully induce remission of post‐ LT GVHD in a pediatric patient.
- 11 August 2024
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 79 (4) , 818-825
Portal vein hypoplasia is present in patients with biliary atresia at the time of diagnosis
Background: In patients with biliary atresia (BA), severe portal hypertension (HTN) develops even with successful bile flow restoration, suggesting an intrinsic factor driving portal HTN independent from bile obstruction. We hypothesize that patients with BA have abnormal portal vein (PV) development, leading to PV hypoplasia.Methods: In this observational cohort study, we enrolled patients who were referred to a tertiary center from 2017 to 2021 to rule out BA. Newborns who underwent computed tomography angiogram as a clinical routine before intraoperative cholangiogram, and laparoscopic Kasai hepatoportoenterostomy. The diameter of the PV and hepatic artery (HA) were compared to the degree of liver fibrosis in the wedge biopsies. The jaundice clearance, native liver survival, and clinical portal hypertensive events, including ascites development and intestinal bleeding, were assessed.Results: 47 newborns with cholestasis were included in the cohort; 35 were diagnosed with BA. The patients with BA had a smaller median PV diameter (4.3 vs. 5.1 mm; p < 0.001) and larger median HA diameter (1.4 vs. 1.2 mm; p < 0.05) compared to the patients with other forms of cholestasis. The median PV and HA diameter did not correlate with the degree of liver fibrosis. Among 35 patients with BA, 29 patients (82.9%) achieved jaundice clearance, and 23 patients (65.7%) were alive with their native liver at two years of age. Seven patients (20%) developed intestinal bleeding, and seven patients (20%) developed ascites, with one overlapping patient.Conclusion: PV hypoplasia is present in patients with BA independent of liver fibrosis at the time of diagnosis.
- 11 August 2024
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 79 (4) , 818-825
Portal vein hypoplasia is present in patients with biliary atresia at the time of diagnosis
Background: In patients with biliary atresia (BA), severe portal hypertension (HTN) develops even with successful bile flow restoration, suggesting an intrinsic factor driving portal HTN independent from bile obstruction. We hypothesize that patients with BA have abnormal portal vein (PV) development, leading to PV hypoplasia.Methods: In this observational cohort study, we enrolled patients who were referred to a tertiary center from 2017 to 2021 to rule out BA. Newborns who underwent computed tomography angiogram as a clinical routine before intraoperative cholangiogram, and laparoscopic Kasai hepatoportoenterostomy. The diameter of the PV and hepatic artery (HA) were compared to the degree of liver fibrosis in the wedge biopsies. The jaundice clearance, native liver survival, and clinical portal hypertensive events, including ascites development and intestinal bleeding, were assessed.Results: 47 newborns with cholestasis were included in the cohort; 35 were diagnosed with BA. The patients with BA had a smaller median PV diameter (4.3 vs. 5.1 mm; p < 0.001) and larger median HA diameter (1.4 vs. 1.2 mm; p < 0.05) compared to the patients with other forms of cholestasis. The median PV and HA diameter did not correlate with the degree of liver fibrosis. Among 35 patients with BA, 29 patients (82.9%) achieved jaundice clearance, and 23 patients (65.7%) were alive with their native liver at two years of age. Seven patients (20%) developed intestinal bleeding, and seven patients (20%) developed ascites, with one overlapping patient.Conclusion: PV hypoplasia is present in patients with BA independent of liver fibrosis at the time of diagnosis.
- Open Access
- 22 March 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (4)
Rapid in vivo evaluation system for cholestasis-related genes in mice with humanized bile acid profiles
Background: Pediatric cholestatic liver diseases (Ped-CLD) comprise many ultrarare disorders with a genetic basis. Pharmacologic therapy for severe cases of Ped-CLD has not been established. Species differences in bile acid (BA) metabolism between humans and rodents contribute to the lack of phenocopy of patients with Ped-CLD in rodents and hinder the development of therapeutic strategies. We aimed to establish an efficientin vivosystem to understand BA-related pathogenesis, such as Ped-CLD.Methods: We generated mice that express spCas9 specifically in the liver (L-Cas9Tg/Tg[liver-specific Cas9Tg/Tg] mice) and designed recombinant adeno-associated virus serotype 8 encoding small-guide RNA (AAV8 sgRNA) targetingAbcc2,Abcb11, andCyp2c70. In humans,ABCC2andABCB11deficiencies cause constitutional hyperbilirubinemia and most severe Ped-CLD, respectively.Cyp2c70encodes an enzyme responsible for the rodent-specific BA profile. Six-week-old L-Cas9Tg/Tgmice were injected with this AAV8 sgRNA and subjected to biochemical and histological analysis.Results: Fourteen days after the injection with AAV8 sgRNA targetingAbcc2, L-Cas9Tg/Tgmice exhibited jaundice and phenocopied patients withABCC2deficiency. L-Cas9Tg/Tgmice injected with AAV8 sgRNA targetingAbcb11showed hepatomegaly and cholestasis without histological evidence of liver injury. Compared toAbcb11alone, simultaneous injection of AAV8 sgRNA forAbcb11andCyp2c70humanized the BA profile and caused higher transaminase levels and parenchymal necrosis, resembling phenotypes withABCB11deficiency.Conclusions: This study provides proof of concept for efficientin vivoassessment of cholestasis-related genes in humanized bile acid profiles. Our platform offers a more time- and cost-effective alternative to conventional genetically engineered mice, increasing our understanding of BA-related pathogenesis such as Ped-CLD and expanding the potential for translational research.
- 22 March 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (4)
Open AccessRapid in vivo evaluation system for cholestasis-related genes in mice with humanized bile acid profiles
Background: Pediatric cholestatic liver diseases (Ped-CLD) comprise many ultrarare disorders with a genetic basis. Pharmacologic therapy for severe cases of Ped-CLD has not been established. Species differences in bile acid (BA) metabolism between humans and rodents contribute to the lack of phenocopy of patients with Ped-CLD in rodents and hinder the development of therapeutic strategies. We aimed to establish an efficientin vivosystem to understand BA-related pathogenesis, such as Ped-CLD.Methods: We generated mice that express spCas9 specifically in the liver (L-Cas9Tg/Tg[liver-specific Cas9Tg/Tg] mice) and designed recombinant adeno-associated virus serotype 8 encoding small-guide RNA (AAV8 sgRNA) targetingAbcc2,Abcb11, andCyp2c70. In humans,ABCC2andABCB11deficiencies cause constitutional hyperbilirubinemia and most severe Ped-CLD, respectively.Cyp2c70encodes an enzyme responsible for the rodent-specific BA profile. Six-week-old L-Cas9Tg/Tgmice were injected with this AAV8 sgRNA and subjected to biochemical and histological analysis.Results: Fourteen days after the injection with AAV8 sgRNA targetingAbcc2, L-Cas9Tg/Tgmice exhibited jaundice and phenocopied patients withABCC2deficiency. L-Cas9Tg/Tgmice injected with AAV8 sgRNA targetingAbcb11showed hepatomegaly and cholestasis without histological evidence of liver injury. Compared toAbcb11alone, simultaneous injection of AAV8 sgRNA forAbcb11andCyp2c70humanized the BA profile and caused higher transaminase levels and parenchymal necrosis, resembling phenotypes withABCB11deficiency.Conclusions: This study provides proof of concept for efficientin vivoassessment of cholestasis-related genes in humanized bile acid profiles. Our platform offers a more time- and cost-effective alternative to conventional genetically engineered mice, increasing our understanding of BA-related pathogenesis such as Ped-CLD and expanding the potential for translational research.
- Open Access
- 14 March 2024
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 39, 101069
Induced pluripotent stem cell (iPSC) modeling validates reduced GBE1 enzyme activity due to a novel variant, p.Ile694Asn, found in a patient with suspected glycogen storage disease IV
- 14 March 2024
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 39, 101069
Open AccessInduced pluripotent stem cell (iPSC) modeling validates reduced GBE1 enzyme activity due to a novel variant, p.Ile694Asn, found in a patient with suspected glycogen storage disease IV
- Open Access
- 1 December 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (12)
Neonatal cholestasis in children with Alpha-1-AT deficiency is a risk for earlier severe liver disease with male predominance
Background: Our objective was to better understand the natural history and disease modifiers of Alpha-1-antitrypsin deficiency (AATD), a common genetic liver disease causing hepatitis and cirrhosis in adults and children. The clinical course is highly variable. Some infants present with neonatal cholestasis, which can resolve spontaneously or progress to cirrhosis; others are well in infancy, only to develop portal hypertension later in childhood. Methods: The Childhood Liver Disease Research Network has been enrolling AATD participants into longitudinal, observational studies at North American tertiary centers since 2004. We examined the clinical courses of 2 subgroups of participants from the several hundred enrolled; first, those presenting with neonatal cholestasis captured by a unique study, enrolled because of neonatal cholestasis but before specific diagnosis, then followed longitudinally (n=46); second, separately, all participants who progressed to liver transplant (n=119). Results: We found male predominance for neonatal cholestasis in AATD (65% male, p=0.04), an association of neonatal gamma-glutamyl transpeptidase elevation to more severe disease, and a higher rate of neonatal cholestasis progression to portal hypertension than previously reported (41%) occurring at median age of 5 months. Participants with and without preceding neonatal cholestasis were at risk of progression to transplant. Participants who progressed to liver transplant following neonatal cholestasis were significantly younger at transplant than those without neonatal cholestasis (4.1 vs. 7.8 years, p=0.04, overall range 0.3–17 years). Neonatal cholestasis had a negative impact on growth parameters. Coagulopathy and varices were common before transplant, but gastrointestinal bleeding was not. Conclusions: Patients with AATD and neonatal cholestasis are at risk of early progression to severe liver disease, but the risk of severe disease extends throughout childhood. Careful attention to nutrition and growth is needed.
- 1 December 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (12)
Open AccessNeonatal cholestasis in children with Alpha-1-AT deficiency is a risk for earlier severe liver disease with male predominance
Background: Our objective was to better understand the natural history and disease modifiers of Alpha-1-antitrypsin deficiency (AATD), a common genetic liver disease causing hepatitis and cirrhosis in adults and children. The clinical course is highly variable. Some infants present with neonatal cholestasis, which can resolve spontaneously or progress to cirrhosis; others are well in infancy, only to develop portal hypertension later in childhood. Methods: The Childhood Liver Disease Research Network has been enrolling AATD participants into longitudinal, observational studies at North American tertiary centers since 2004. We examined the clinical courses of 2 subgroups of participants from the several hundred enrolled; first, those presenting with neonatal cholestasis captured by a unique study, enrolled because of neonatal cholestasis but before specific diagnosis, then followed longitudinally (n=46); second, separately, all participants who progressed to liver transplant (n=119). Results: We found male predominance for neonatal cholestasis in AATD (65% male, p=0.04), an association of neonatal gamma-glutamyl transpeptidase elevation to more severe disease, and a higher rate of neonatal cholestasis progression to portal hypertension than previously reported (41%) occurring at median age of 5 months. Participants with and without preceding neonatal cholestasis were at risk of progression to transplant. Participants who progressed to liver transplant following neonatal cholestasis were significantly younger at transplant than those without neonatal cholestasis (4.1 vs. 7.8 years, p=0.04, overall range 0.3–17 years). Neonatal cholestasis had a negative impact on growth parameters. Coagulopathy and varices were common before transplant, but gastrointestinal bleeding was not. Conclusions: Patients with AATD and neonatal cholestasis are at risk of early progression to severe liver disease, but the risk of severe disease extends throughout childhood. Careful attention to nutrition and growth is needed.
- 5 November 2022
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 58 (8) , 1483-1488
Customized Postoperative Therapy Improves Bile Drainage in Biliary Atresia: A Single Center Preliminary Report
- 5 November 2022
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 58 (8) , 1483-1488
Customized Postoperative Therapy Improves Bile Drainage in Biliary Atresia: A Single Center Preliminary Report
- 25 October 2022
- Published by Wiley in JPGN Reports
- Vol. 3 (4) , e267
Open AccessGas Leak in the Port
- 1 June 2022
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 75 (2) , 131-137
The Outcome of Patients With Cystic Biliary Atresia With Intact Proximal Hepatic Ducts Following Hepatic‐Cyst‐Jejunostomy
Objectives: To determine the outcomes of patients with cystic biliary atresia by correlating the anatomy of the hepatic ducts with the choice of biliary reconstruction surgery.Background: The Kasai hepatoportoenterostomy (Kasai) is the initial surgical procedure offered to most patients with biliary atresia. In contrast, a hepatic‐cyst‐jejunostomy has been reported to be effective in patients with the cystic form of biliary atresia.Methods and Results: We performed an international multicenter retrospective review. Two hundred eighty‐seven patients were included, and 33 cases of cystic biliary atresia were identified. Outcomes were the serum total bilirubin level 3 months post‐surgery and native liver survival at 2 years of age and were compared between cases who received the Kasai versus hepatic‐cyst‐jejunostomy in correlation to the anatomy of proximal hepatic ducts. The patients were categorized into 3 anatomical groups: patent intact hepatic ducts (n = 10), patent hypoplastic hepatic ducts (n = 13), and obliterated hepatic ducts (n = 10). All 10 patients with patent intact hepatic duct group underwent hepatic‐cyst‐jejunostomy, and 9 experienced bile drainage and native liver survival. Among the 13 patients with hypoplastic hepatic ducts, 11 underwent the Kasai procedure, and 9 had bile drainage, whereas 2 underwent hepatic‐cyst‐jejunostomy, and one survived with the native liver. All of the patients with obliterated hepatic ducts underwent the Kasai procedure; 5 established biliary drainage and survived with the native liver. Of 5 who did not drain, 3 underwent liver transplantation.Conclusions: In patients with cystic biliary atresia, the subset with a connection between cyst and intrahepatic bile ducts via intact proximal hepatic ducts had favorable clinical outcomes following hepatic‐cyst‐jejunostomy.
- 1 June 2022
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 75 (2) , 131-137
The Outcome of Patients With Cystic Biliary Atresia With Intact Proximal Hepatic Ducts Following Hepatic‐Cyst‐Jejunostomy
Objectives: To determine the outcomes of patients with cystic biliary atresia by correlating the anatomy of the hepatic ducts with the choice of biliary reconstruction surgery.Background: The Kasai hepatoportoenterostomy (Kasai) is the initial surgical procedure offered to most patients with biliary atresia. In contrast, a hepatic‐cyst‐jejunostomy has been reported to be effective in patients with the cystic form of biliary atresia.Methods and Results: We performed an international multicenter retrospective review. Two hundred eighty‐seven patients were included, and 33 cases of cystic biliary atresia were identified. Outcomes were the serum total bilirubin level 3 months post‐surgery and native liver survival at 2 years of age and were compared between cases who received the Kasai versus hepatic‐cyst‐jejunostomy in correlation to the anatomy of proximal hepatic ducts. The patients were categorized into 3 anatomical groups: patent intact hepatic ducts (n = 10), patent hypoplastic hepatic ducts (n = 13), and obliterated hepatic ducts (n = 10). All 10 patients with patent intact hepatic duct group underwent hepatic‐cyst‐jejunostomy, and 9 experienced bile drainage and native liver survival. Among the 13 patients with hypoplastic hepatic ducts, 11 underwent the Kasai procedure, and 9 had bile drainage, whereas 2 underwent hepatic‐cyst‐jejunostomy, and one survived with the native liver. All of the patients with obliterated hepatic ducts underwent the Kasai procedure; 5 established biliary drainage and survived with the native liver. Of 5 who did not drain, 3 underwent liver transplantation.Conclusions: In patients with cystic biliary atresia, the subset with a connection between cyst and intrahepatic bile ducts via intact proximal hepatic ducts had favorable clinical outcomes following hepatic‐cyst‐jejunostomy.
- Open Access
- 26 April 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (4) , 110730
In vivo partial cellular reprogramming enhances liver plasticity and regeneration
- 26 April 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (4) , 110730
Open AccessIn vivo partial cellular reprogramming enhances liver plasticity and regeneration